- Home
- ROIV vs DCI Comparison
ROIV vs DCI Comparison
Compare ROIV & DCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | DCI |
|---|---|---|
| Founded | 2014 | 1915 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Pollution Control Equipment |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7B | 10.6B |
| IPO Year | 2021 | 2005 |
Fundamental Metrics
Financial Performance| Metric | ROIV | DCI |
|---|---|---|
| Price | $35.74 | $88.19 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 8 |
| Target Price | $48.08 | ★ $100.40 |
| AVG Volume (30 Days) | ★ 6.9M | 494.3K |
| Earning Date | 11-09-2026 | 08-26-2026 |
| Dividend Yield | N/A | ★ 1.47% |
| EPS Growth | N/A | ★ 26.23 |
| EPS | N/A | ★ 3.85 |
| Revenue | $8,260,000.00 | ★ $2,844,900,000.00 |
| Revenue This Year | $530.75 | $7.86 |
| Revenue Next Year | $685.92 | $4.88 |
| P/E Ratio | ★ N/A | $22.75 |
| Revenue Growth | N/A | ★ 4.05 |
| 52 Week Low | $15.25 | $79.61 |
| 52 Week High | $42.50 | $112.84 |
Technical Indicators
Market Signals| Indicator | ROIV | DCI |
|---|---|---|
| Relative Strength Index (RSI) | 46.25 | 39.95 |
| Support Level | $33.15 | $86.41 |
| Resistance Level | $37.59 | $87.80 |
| Average True Range (ATR) | 1.21 | 1.49 |
| MACD | -0.40 | 0.20 |
| Stochastic Oscillator | 22.31 | 48.81 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About DCI Donaldson Company Inc.
Donaldson is a leading manufacturer of filtration systems and replacement parts, including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors. The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.9 billion in revenue in its fiscal 2026.